The TriTAC (tri-specific T cell activating construct) platform represents Harpoon Therapeutics' core technology for developing novel T cell engagers. This platform is designed to redirect a patient's own T cells to target and destroy cancer cells expressing specific tumor-associated antigens. Research and development activities within this segment focus on optimizing the TriTAC molecule for enhanced potency, specificity, and safety. Key methodologies include protein engineering, antibody design, and preclinical in vivo studies to evaluate anti-tumor activity. The therapeutic areas targeted by TriTAC-based therapies include small cell lung cancer, multiple myeloma, ovarian cancer, and pancreatic cancer. By leveraging the TriTAC platform, Harpoon aims to provide more effective and less toxic treatment options for patients with advanced cancers, addressing significant unmet medical needs. Future opportunities involve expanding the platform to target additional tumor antigens and exploring combination therapies to further improve patient outcomes. Clinical trials are essential for validating the safety and efficacy of TriTAC-based product candidates.

Harpoon Therapeutics' oncology pipeline encompasses a range of clinical-stage immunotherapies designed to address various solid tumors and hematological malignancies. This segment focuses on the development and clinical evaluation of product candidates such as HPN328, HPN217, and HPN536. Research and development efforts involve conducting Phase 1/2 clinical trials to assess the safety, tolerability, and efficacy of these therapies in patients with small cell lung cancer, multiple myeloma, ovarian cancer, and pancreatic cancer. Technologies and methodologies employed include biomarker analysis, patient stratification, and advanced imaging techniques to monitor treatment response. The therapeutic areas covered within this segment are primarily focused on cancers with high unmet medical needs, aiming to improve patient survival and quality of life. Market positioning involves establishing Harpoon as a leader in T cell engager therapies for oncology, with a competitive advantage in its TriTAC platform. Future opportunities include expanding the pipeline through strategic partnerships and collaborations, as well as exploring new indications for existing product candidates. Regulatory and clinical aspects are critical, with ongoing efforts to obtain regulatory approvals and advance clinical development programs.